• Testosterone Bounce in Degarelix-Treated Prostate Cancer

  2026-09-29

  This retrospective study identified testosterone bounce, defined by recovery above 20 ng/dL after reaching a nadir below that threshold, as a marker associated with longer overall and cancer-specific survival in patients receiving degarelix. The findings support serial testosterone assessment as a complementary prognostic approach, while the absence of an association with progression-free survival highlights important limits to interpretation.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-09-28

  This case report describes radiographic reduction of metastatic intra-abdominal desmoplastic small round cell tumor after treatment with anlotinib, offering an early clinical signal in a malignancy without standardized therapy. Its value lies in connecting a multi-target tyrosine kinase inhibitor with a rare, aggressive tumor while also illustrating the diagnostic, imaging, and tolerability considerations required for interpretation.

• Anlotinib Hydrochloride: Anti-Angiogenic Evidence

  2026-09-28

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor used in preclinical research on angiogenesis and tumor growth. Evidence links VEGFR2 inhibition with reduced endothelial responses, while reported multi-target activity supports studying PDGFRβ, FGFR1, and ERK signaling in parallel.

• Hoechst 33342 in Fibroblast Senescence Workflows

  2026-09-27

  Use Hoechst 33342 to visualize and count nuclei in live or fixed dermal fibroblasts—an important imaging readout, but not a stand-alone measure of senescence or mitochondrial health. This workflow pairs nuclear labeling with the complementary assays used to study pterostilbene and mitochondrial quality in human dermal fibroblasts.

• Separating Growth Arrest from Cell Death in Cancer Assays

  2026-09-26

  Hannah R. Schwartz’s dissertation highlights a central problem in in vitro cancer-drug evaluation: relative viability and fractional viability are often treated as interchangeable, even though they reflect different components of response. Its findings support measuring growth inhibition and cell killing separately and considering how their relative contributions change over time.

• Bufalin and the CENPA–Glycolysis Axis in HCC

  2026-09-25

  New pre-proof evidence connects Bufalin with CENPA-associated glycolysis, PI3K/AKT signaling, and migration in hepatocellular carcinoma models. This article examines what the findings establish, what remains to be tested, and how translational teams can design stronger validation workflows.

• Anlotinib and Selective VEGFR2 Inhibition in Angiogenesis

  2026-09-25

  The 2018 preclinical study characterized anlotinib as a potent, selective VEGFR2 inhibitor and linked receptor inhibition to reduced endothelial responses and tumor angiogenesis. Its layered biochemical, cell-based, explant, and mouse experiments provide a useful framework for evaluating anti-angiogenic activity, while leaving clinical efficacy and transferability to human tumors unresolved.

• Anlotinib Hydrochloride for Angiogenesis Assays

  2026-09-24

  Use Anlotinib hydrochloride to connect VEGFR2, PDGFRβ, and FGFR1 blockade with measurable changes in endothelial migration, tube formation, and ERK signaling. This workflow-focused guide helps researchers select complementary assays, set practical starting conditions, and separate anti-angiogenic effects from cytotoxicity.

• (S)-(+)-Dimethindene maleate: Research Guide

  2026-09-24

  (S)-(+)-Dimethindene maleate is an M2 muscarinic receptor antagonist for controlled receptor and physiology experiments, with additional H1 antagonist activity that should be considered during interpretation. This guide covers preparation, assay controls, and handling; the compound is for research use only, not for diagnostic or medical applications.

• 3-Deazaadenosine Hydrochloride in Methylation Studies

  2026-09-23

  3-Deazaadenosine hydrochloride is a selective S-adenosylhomocysteine hydrolase inhibitor for research on SAHH-dependent methyl metabolism. The IGF2BP1–TUBB4B liver-fibrosis study provides a relevant m6A pathway context, but does not establish that this compound changes that pathway or hepatic stellate cell behavior.

• Red Blood Cell Membrane Bending Rigidity: Key Findings

  2026-09-23

  Himbert et al. separated the bending response of the red blood cell cytoplasmic membrane from that of the spectrin cytoskeleton by combining X-ray diffuse scattering, neutron spin-echo spectroscopy, and molecular dynamics simulations. Their estimate of approximately 4–6 kBT indicates that the isolated membrane is considerably softer than many previously reported whole-cell or composite-membrane measurements, clarifying how scale and structural composition shape RBC mechanics.

• Direct Mouse Genotyping Kit Plus: Workflow

  2026-09-22

  The Direct Mouse Genotyping Kit Plus supports rapid mouse genomic DNA extraction and direct PCR amplification without a purification step. Its PCR master mix with dye reagents streamlines genotype screening, while the cited EP4 study provides a biologically relevant example of why accurate mouse genotype confirmation matters.

• Cy3-dCTP: Designing Better Fluorescent Assays

  2026-09-22

  Cy3-dCTP enables direct fluorescent labeling of DNA and cDNA, but assay performance also depends on polymerase access and substrate geometry. This guide connects Cyanine 3-deoxycytidine triphosphate chemistry with recent DNA-framework research to support better labeling decisions.

• From Microglial Mechanisms to Better Western Blots

  2026-09-21

  Mechanistic studies of intracerebral hemorrhage increasingly depend on precise protein measurement. This thought-leadership guide connects EMSC-driven microglial regulation through NF-κB and MAPK with practical western blot strategy, showing how sensitive ECL workflows can strengthen translational confidence without overstating preclinical evidence.

• EZ Cap™ Human PTEN mRNA (ψUTP) Workflow

  2026-09-21

  A practical research workflow for using Cap 1, pseudouridine-modified PTEN mRNA to study tumor-suppressor restoration and PI3K/Akt signaling. Learn how to pair this defined in vitro transcribed mRNA with mammalian transfection, nanoparticle delivery, resistance models, and troubleshooting controls.

8057 records 2/538 page Previous Next 12345 下5页 Last page